Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zai Lab Ltd ( (HK:9688) ) has issued an update.
Zai Lab has called its 2026 annual general meeting for June 17, 2026, in Shanghai with a concurrent virtual option, setting April 16, 2026, as the record date for shareholders eligible to vote. The hybrid format is designed to increase accessibility for its global investor base while maintaining a physical presence in its key China market.
Shareholders will vote on the re‑election of nine directors to serve until the 2027 meeting, as well as the appointment of KPMG entities as auditors for the 2026 financial year and authorization for the board to set auditor compensation. The agenda also includes an advisory vote on executive compensation and a general mandate for the board to issue up to 10% of the company’s share capital, decisions that will shape Zai Lab’s governance, capital flexibility, and investor oversight in the coming year.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands and listed in Hong Kong, focusing on the development and commercialization of innovative medicines. The company operates in China and global markets, targeting high unmet medical needs through a portfolio of oncology, autoimmune, and infectious disease therapies.
Average Trading Volume: 11,148,324
Technical Sentiment Signal: Sell
Current Market Cap: HK$19.93B
Learn more about 9688 stock on TipRanks’ Stock Analysis page.